  Elusys Therapeutics, Inc. (Pine Brook, NJ, 

), a biotechnology company  developing targeted anti-infective antibodies to fight life-threatening  infections, has entered into an exclusive collaborative research and license  agreement with Pfizer, Inc. (New York, NY, 

)  to develop new therapeutics for select infectious diseases using Elusys’s HP  antibody technology. 

The research collaboration will include ETI-211, an HP  Antibody for the treatment of methicillin-resistant Staphylococcus aureus  infections, in addition to research into other indications. Under the terms of  the agreement, Elusys and Pfizer will collaborate on determining the full  product profile of ETI-211 and perform research on other indications of  the HP Antibody technology. 

Elusys will receive an upfront equity investment,  research and development funding, and near-term research milestones. Elusys  has also granted Pfizer an option to acquire an exclusive worldwide license to  products developed under the agreement, and upon exercise, the company will  receive significant clinical and sales milestones, as well as royalties on  future sales of products resulting from the collaboration.

News

Elusys Therapeutics, Inc. (Pine Brook, NJ, www.elusys.com), a biotechnology company developing targeted anti-infective antibodies to fight life-threatening infections, has entered into an exclusive collaborative research and license agreement with Pfizer, Inc. (New York, NY, www.pfizer.com) to develop new therapeutics for select infectious diseases using Elusys's HP antibody technology.